Alpa Laboratories Ltd (NSE: ALPA, BSE: 532878) is a Indore, Madhya Pradesh-based company in the Pharmaceuticals industry. With a market capitalisation of ₹112 Cr, it ranks #3,170 by market cap among the 6,137 Indian listed companies on FinBizNet, and #42 of 63 in Pharmaceuticals. At ₹49.29 (as of 25 Oct 2026), the share price is 47.5% below its 52-week high of ₹93.85 and 6.9% above its 52-week low of ₹46.10. The share price is down 44.2% over one year and down 26.6% over three months.
| Current Price | ₹49.29 |
|---|---|
| Market Cap | ₹112 Cr |
| NSE Symbol | ALPA |
| BSE Code | 532878 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 7.3 |
| Return on Equity | 8.39% |
| Return on Assets | 0.32% |
| 52-Week Range | ₹46.10 – ₹93.85 |
| 1-Year Price Change | -44.2% |
| 3-Month Price Change | -26.6% |
| Beta (1Y) | 1.14 |
| Headquarters | Indore, Madhya Pradesh |
| Website | www.alpalabs.in |
| Revenue | ₹24 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 4.1% |
| EPS (Basic) | ₹0.49 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Alpa Laboratories Limited engages in the manufacture and sale of drugs and chemicals in India. It provides formulations that address various therapeutic segments. The company was incorporated in 1988 and is based in Indore, India.
1. Drugs and Chemicals-This segment manufactures and markets pharmaceutical formulations under its own brand and for various pharmaceutical companies. It offers various products for human use and veterinary products.
1. Drugs and Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Alpa Laboratories Ltd | ₹112 Cr | 7.3 | 8.39% | ₹24 Cr | -44.2% |
Listed by market capitalisation. Ratios are shown for context only.
Alpa Laboratories Ltd is trading at ₹49.29, with a market capitalisation of ₹112 Cr.
Alpa Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Alpa Laboratories Ltd has a P/E of 7.3 and a return on equity of 8.39%.
Alpa Laboratories Ltd is listed on the NSE under the symbol ALPA and on the BSE under the scrip code 532878.
Alpa Laboratories Ltd's share price is down 44.2% over one year and down 26.6% over three months. Its 52-week range is ₹46.10 to ₹93.85.
In Q1 FY27, Alpa Laboratories Ltd reported revenue of ₹24 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.49 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.